our peoplemake us who we are

Our company was co-founded by leading pioneers in precision oncology and RAS targeting—to create novel therapies and combination regimens designed to comprehensively silence the RAS/MAPK pathway for the treatment of cancer.

Our leadership team and employees have broad and deep experience in company building and in oncology, including advancing therapeutic candidates from discovery research to clinical development, regulatory approval, and commercialization.


Jonathan E. Lim, M.D.

Chairman, CEO and Co-founder

David Chacko, M.D.

Chief Financial Officer

Ebun Garner, J.D.

General Counsel

Wei Lin, M.D.

Chief Medical Officer

Board of Directors

Scientific Advisory Board

R&D Advisory Board

Bruce Roth, Ph.D.

Senior Chemistry Advisor

Paul Pearson, Ph.D.

Senior ADME/PK Advisor

Jane Chang, Ph.D.

Senior Toxicology Advisor

James Freddo, M.D.

Senior Medical Advisor